Purpose To evaluate the clinical efficacy and safety of uterine artery embolization (UAE) using N-butyl-2-cyanoacrylate (NBCA) in patients with postpartum hemorrhage (PPH).
INTRODUCTION
Obstetric hemorrhage is one of the major causes of maternal mortality and is responsible for about 25% of maternal deaths (1) . Initial conservative treatment methods for postpartum hemorrhage (PPH) include administration of uterotonic agents, uterine massage, vaginal packing, and transfusion (2) . Recently, intrauterine balloon tamponade has been attempted, and the success rate was reported to be approximately 83% (3) . However, when the conservative treatments fail, surgery or transcatheter arterial embolization (TAE) should be considered as the next treatment option.
Since uterine artery embolization (UAE) was introduced, it has been accepted as one of the most effective treatments for intractable PPH, with high success rates (4) (5) (6) . The most commonly used material in UAE for PPH is gelatin sponge particles, and these help in spontaneous resolution within three to six weeks. Gelatin sponge particles were chosen due to the concern about the negative impact on fertility owing to permanent devascularization of the uterus (7) . However, when treating patients with coagulopathy or hemodynamic instability, gelatin sponge particles are often not effective and conversion to a permanent embolic material should be considered (8, 9) . N-butyl-2-cyanoacrylate (NBCA) has emerged as a potent permanent embolic material in the treatment of acute hemorrhage of various etiologies because of its rapid intravascular polymerization (10) (11) (12) . It has gained increasing attention, especially in embolization for coagulopathic patients (13) . However, the use of NBCA is generally avoided due to its rapid polymerization as well as permanent embolic property.
In case of PPH, previous reports suggest that NBCA was effective in patients with coagulopathy and pseudoaneurysm or extravasation (14) (15) (16) (17) . However, there are only a few reports of the use of NBCA in patients with PPH.
Therefore, the purpose of our study was to evaluate the efficacy and safety of UAE using NBCA in patients with PPH.
MATERIALS AND METHODS

PATIENT SELECTION AND BASIC CHARACTERISTICS
Our Institutional Review Board approved this retrospective study, and the requirement for informed consent was waived. We retrospectively reviewed the medical records of 82 patients who underwent TAE for PPH from February 2010 to May 2018. Of these, 14 (17.1%) patients (age range: 28-39 years; mean age: 33 years) underwent UAE using NBCA. The inclusion criteria for the use of NBCA were the visualization of extravasation or pseudoaneurysm on angiography and the achievement of selective catheterization of the microcatheter at the bleeding focus. The initial laboratory findings and basic characteristics of these patients are listed in Table 1 .
EMBOLIZATION PROCEDURE
Before the patients were transferred to the angiography room, dual-phase computed tomographic (CT) angiography was performed in possible cases with a slice thickness of 1.3 NBCA in Patients with Postpartum Hemorrhage mm. One of two interventional radiologists (each with 10 and 13 years of experience) performed the TAE. A 5F vascular sheath was introduced via the right or left common femoral artery using the Seldinger technique. In patients with a weak femoral arterial pulse, an arterial puncture was performed using a Micropuncture© Access Set (Cook Medical, Bloomington, IN, USA), under ultrasound guidance. When the focus of bleeding was identified on CT angiography, pelvic aortography was not performed. In the cases where CT scan was not performed, pelvic aortography was performed with a 5F pigtail catheter (Cook Medical) to evaluate pelvic arterial anatomy and identify the bleeding focus. After the bleeding focus was confirmed, selective arteriography and UAE were performed using a 1.98-2.3F microcatheter (Asahi Masters Parkway Soft; Asahi, Nagoya, Japan; Progreat, Terumo, Tokyo, Japan; Microferret, Cook Medical). When the extravasation or pseudoaneurysm was noticed and selective catheterization was achieved, NBCA was used. A mixture of NBCA and iodized oil (Lipiodol, Guerbet, Aulnay-Sous-Bois, France), mixed in a ratio of 1:1 to 1:3, was used. After UAE, the obstetrician performed a vaginal examination to ensure adequate control of bleeding. In the event of persistent vaginal bleeding, arteriography including aortography above the level of renal arteries was performed to detect another bleeding source. If another bleeding focus was identified, additional embolization was performed.
DATA ANALYSIS AND DEFINITION
We evaluated clinical and angiographic findings, procedure-related complications, and technical and clinical success rates. Primary PPH was defined as blood loss of more than 500 mL in the first 24 hours following birth (2) . Secondary PPH was defined as blood loss of more than 500 mL after the first day and up to six weeks after birth (2) . Hemodynamic instability was defined as systolic blood pressure < 90 mm Hg and fluid resuscitation requirement > 2000 mL or requirement of a blood transfusion of > 4 units within 24 hours (18, 19) . We defined technical success as complete embolization of the target arteries, and clinical success as the cessation of bleeding on vaginal examination without need for additional surgical management during the patient's admission period. We defined patients with a prothrombin ratio greater than 1.5 or a platelet count of less than 80000/µL as coagulopathic (15, 20) . Complications were categorized into major or minor types. Major complications included those requiring prolonged hospitalization, causing permanent adverse sequelae, or death. Minor complications were those requiring no treatment or treatment by an interventionist in an angiography room without prolonged hospitalization or adverse consequences (21) .
RESULTS
Out of 82 patients, 14 (17.1%) underwent UAE using NBCA. Before transfer to the angiography room, uterotonic agents were administrated in 11 patients. Two patients were transferred to the emergency room after hysterectomy performed at other hospitals. We found primary and secondary PPH in 11 (78.6%) and 3 (21.4%) patients, respectively, out of the 14.
In two patients, intrauterine balloon (Bakri, Cook Medical) tamponade was attempted at the discretion of the obstetrician. The initial hemoglobin levels ranged from 3.7 g/dL to 9.8 g/dL (mean: 7 g/dL), and coagulopathy was present in 5 (35.7%) patients. The major causes of PPH were hysterotomy-or hysterectomy-related arterial injury (n = 11) ( Fig. 1 ), cervical laceration (n = 2) ( Fig. 2) , and abnormal placentation (n = 1). In all the patients, UAE was performed with NBCA. Additional UAE with gelatin sponge particles was performed due to combined uterine atony in two patients. Additional embolization for inferior epigastric artery (IEA) was Among five patients with coagulopathy, we observed one technical and two clinical failures.
Immediate hysterectomy was performed in two patients at the obstetrician's discretion. One patient who survived cardiopulmonary resuscitation died from multi-organ failure eight days after UAE. One patient with abnormal placentation that was a combination of placenta 
DISCUSSION
Permanent embolic materials have not been commonly used in patients with PPH be- (22) . They used NBCA in patients with pseudoaneurysm. Since then, a few articles have reported the use of NBCA in patients with PPH who showed extravasation or pseudoaneurysm, and the success rates were 67.9-92.3% (14, 15) . In our study, we performed UAE using NBCA and achieved high technical (92.9%) and clinical success (85.7%) rates with low complication rates.
In our cases, we observed uterine artery rupture or pseudoaneurysm in 11 patients. In most cases, the lesions usually occurred at the proximal portion of the ascending segment of the uterine artery, which made it possible to use NBCA because there was no need to advance the microcatheter to the distal uterine artery through the tortuous ascending segment of the uterine artery. However, in one case of uterine fundal bleeding, we advanced the microcatheter through the tortuous segment and performed successful UAE (Fig. 3) . When the microcatheter is not wedged into the vessel, NBCA runs through the vessel with arterial flow until it is polymerized. In previous reports, when NBCA was diluted to 50% with Lipiodol, the polymerization time of the 50% of the NBCA and Lipiodol mixture was six to ten seconds in the in-vitro experiments that could be replicated in the in-vivo environments under vessel wall interaction (23, 24) . In our experience, NBCA did not advance rapidly in the uterine artery because of its tortuosity. Therefore, in TAE of the uterine artery, it should be considered that the distance traversed by NBCA might be shorter than expected.
In our study, there were two cases of cervical artery bleeding. In these cases, considering the complex pelvic arterial anatomy and collateral arteries that developed during pregnancy, embolization of the bleeding focus as well as its proximal and distal segments was needed for successful embolization (25) . Therefore, we chose NBCA as an embolic material in these cases. The extent of embolization with NBCA could be controlled by wedging the catheter into the target vessel, as NBCA is a liquid embolic material. By doing this, we could embolize the bleeding vessel without repeated embolization. In our study, additional embolization for IEA was performed in two patients due to surgical wound bleeding. These bleeding foci were detected on CT angiography before the embolization procedures and these might have been missed if not for the CT scan. Therefore, detection of the bleeding focus with a CT scan is important for successful hemostasis in patients with PPH (26).
One patient experienced pelvic ischemia after repeated embolization. However, considering that the NBCA was used only for UAE, this could be deemed unrelated to the use of NBCA. In this patient, to our knowledge, pelvic ischemia resulted from multiple pelvic arterial embolizations with gelatin sponge particles. We performed embolization with NBCA only when the selection of the target artery was successfully achieved. By doing this, we could avoid unexpected embolization of the vessels that we did not want to embolize permanently. Therefore, we conclude that the occurrence of complication was determined, not by the kind of embolic material, but by the extent and number of arteries that were embolized.
In our study, we observed clinical failure in two (14.3%) patients. These patients were in coagulopathy at the time of UAE. Of these, one patient underwent UAE with NBCA, but the persistent vaginal bleeding was due to severe disseminated intravascular coagulation (DIC).
Another patient showed multiple and massive bleeding foci which could not be controlled by embolization due to placenta previa combined with placenta percreta. Therefore, our study reveals that the possibility of clinical failure increases in patients with coagulopathy combined with multiple bleeding sources or severe DIC.
Our study has some limitations that warrant consideration. It was limited first by its retrospective nature and second by the small number of patients. In particular, we observed coagulopathy in five patients, and they showed a relatively lower success rate (3/5, 60%) than that reported in previous studies (67.9-90.5%) (14, 15) . With more cases, we could have clearly identified the factors contributing to failure in coagulopathic patients. In addition, future prospective studies are needed for the appropriate selection of patients with PPH for whom the use of NBCA will be suitable.
In conclusion, UAE using NBCA is safe and effective in patients with PPH showing extravasation or pseudoaneurysm.
